WO1998037100B1 - Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ci - Google Patents
Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ciInfo
- Publication number
- WO1998037100B1 WO1998037100B1 PCT/EP1998/000956 EP9800956W WO9837100B1 WO 1998037100 B1 WO1998037100 B1 WO 1998037100B1 EP 9800956 W EP9800956 W EP 9800956W WO 9837100 B1 WO9837100 B1 WO 9837100B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- xqhnpr
- therapeutic
- smr1
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
La présente invention concerne l'utilisation d'une molécule peptidique consistant en un produit de maturation de SMR1 (protéine 1 sous-maxillaire du rat) de formule structurelle QHNPR, ainsi que les dérivés de ce peptide actifs sur le plan biologique, dans la prévention ou le traitement de maladies associées à un déséquilibre en ions minéraux, chez l'homme ou l'animal. Cette invention concerne notamment l'utilisation thérapeutique des molécules ci-dessus, aux fins de prévention ou de traitement d'un déséquilibre hydrominéral dans des organes et tissus comme les reins, les os, l'émail dentaire, l'ivoire dentaire, la matrice intestinale, le pancréas ou la tunique muqueuse de l'estomac. Cette invention concerne encore des compositions thérapeutiques contenant une dose active sur le plan pharmacologique des molécules thérapeutiques ci-dessus décrites, de même que des procédés thérapeutiques dans lesquels on utilise de telles compositions. L'invention concerne enfin des procédés de sélection de molécules coordinats possédant une activité biologique, agoniste ou antagoniste, sur le récepteur cible du pentapeptide QHNPR, de même que ces molécules elles-mêmes.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98912339A EP1007566B1 (fr) | 1997-02-20 | 1998-02-19 | Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ci |
| US09/367,703 US6818405B2 (en) | 1997-02-20 | 1998-02-19 | Therapeutic use of the SMR1 protein and active derivatives thereof |
| CA002281912A CA2281912A1 (fr) | 1997-02-20 | 1998-02-19 | Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ci |
| AU67219/98A AU6721998A (en) | 1997-02-20 | 1998-02-19 | Therapeutic use of the smr1 protein and active derivatives thereof |
| DE69835680T DE69835680T2 (de) | 1997-02-20 | 1998-02-19 | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten |
| US10/620,462 US7429448B2 (en) | 1997-02-20 | 2003-07-17 | Therapeutic use of the SMR1 protein and active derivatives thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/801,405 US6589750B2 (en) | 1997-02-20 | 1997-02-20 | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| US08/801,405 | 1997-02-20 |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/367,703 A-371-Of-International US6818405B2 (en) | 1997-02-20 | 1998-02-19 | Therapeutic use of the SMR1 protein and active derivatives thereof |
| US09367703 A-371-Of-International | 1998-02-19 | ||
| US10/620,462 Division US7429448B2 (en) | 1997-02-20 | 2003-07-17 | Therapeutic use of the SMR1 protein and active derivatives thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998037100A2 WO1998037100A2 (fr) | 1998-08-27 |
| WO1998037100A3 WO1998037100A3 (fr) | 1999-01-07 |
| WO1998037100B1 true WO1998037100B1 (fr) | 1999-03-04 |
Family
ID=25181003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1998/000956 Ceased WO1998037100A2 (fr) | 1997-02-20 | 1998-02-19 | Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ci |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6589750B2 (fr) |
| EP (2) | EP1007566B1 (fr) |
| AT (1) | ATE337339T1 (fr) |
| AU (1) | AU6721998A (fr) |
| CA (1) | CA2281912A1 (fr) |
| DE (1) | DE69835680T2 (fr) |
| DK (1) | DK1007566T3 (fr) |
| ES (1) | ES2271991T3 (fr) |
| PT (1) | PT1007566E (fr) |
| WO (1) | WO1998037100A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| DK1185294T3 (da) * | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
| PT1216707E (pt) * | 2000-12-22 | 2005-06-30 | Pasteur Institut | Novas utilizacoes terapeuticas para um smr-1-peptideo |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2350123T3 (es) | 2003-01-28 | 2011-01-18 | Ironwood Pharmaceuticals, Inc. | Composiciones para el tratamiento de trastornos gastrointestinales. |
| EP1577320B1 (fr) * | 2004-03-19 | 2012-07-18 | Institut Pasteur | Peptides dérivés de la protéine humaine BPLP, polynucléotides les codant et anticorps dirigés contre ces mêmes peptides. |
| DE102004026744A1 (de) * | 2004-05-28 | 2005-12-29 | Philipps-Universität Marburg | Erfindung betreffend cDNA-Herstellung aus Zellen nach Laser-Mikrodissektion |
| AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| PT2274321T (pt) * | 2008-04-07 | 2019-03-21 | Pasteur Institut | Derivados do péptido opiorfina como inibidores potentes da encefalina ¿ degradação de ectopeptidades |
| FR2931362B1 (fr) * | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
| CA2930674A1 (fr) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2828346C (fr) | 2011-03-01 | 2021-01-26 | Synergy Pharmaceuticals Inc. | Procede de preparation d'agonistes du guanylate cyclase c |
| EP2970384A1 (fr) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP4424697A3 (fr) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation |
| CN109212006A (zh) * | 2018-08-24 | 2019-01-15 | 北京艾普希隆生物科技有限公司 | 一种单细胞琼脂糖凝胶电泳试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983003972A1 (fr) | 1982-05-06 | 1983-11-24 | Massachusetts Institute Of Technology | Production d'anticorps neutralisant les enterovirus a partir du vp1 |
| US4699877A (en) | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| GB8327966D0 (en) | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
| IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
| US5219548A (en) * | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
| CA2164966A1 (fr) * | 1993-06-23 | 1995-01-05 | Wolfgang Sadee | Compositions et methodes permettant de mesurer le niveau d'accoutumance a un analgesique narcotique; traitement connexe |
| US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| DK1185294T3 (da) * | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
| PT1216707E (pt) * | 2000-12-22 | 2005-06-30 | Pasteur Institut | Novas utilizacoes terapeuticas para um smr-1-peptideo |
-
1997
- 1997-02-20 US US08/801,405 patent/US6589750B2/en not_active Expired - Lifetime
-
1998
- 1998-02-19 PT PT98912339T patent/PT1007566E/pt unknown
- 1998-02-19 CA CA002281912A patent/CA2281912A1/fr not_active Abandoned
- 1998-02-19 ES ES98912339T patent/ES2271991T3/es not_active Expired - Lifetime
- 1998-02-19 DE DE69835680T patent/DE69835680T2/de not_active Expired - Lifetime
- 1998-02-19 AU AU67219/98A patent/AU6721998A/en not_active Abandoned
- 1998-02-19 EP EP98912339A patent/EP1007566B1/fr not_active Expired - Lifetime
- 1998-02-19 EP EP06009596A patent/EP1702929A3/fr not_active Withdrawn
- 1998-02-19 AT AT98912339T patent/ATE337339T1/de active
- 1998-02-19 WO PCT/EP1998/000956 patent/WO1998037100A2/fr not_active Ceased
- 1998-02-19 DK DK98912339T patent/DK1007566T3/da active
- 1998-02-19 US US09/367,703 patent/US6818405B2/en not_active Expired - Fee Related
-
2003
- 2003-05-12 US US10/435,564 patent/US20030195155A1/en not_active Abandoned
- 2003-07-17 US US10/620,462 patent/US7429448B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998037100B1 (fr) | Utilisation therapeutique de la proteine smr1 ainsi que des derives actifs de celle-ci | |
| Sporn et al. | von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively | |
| Nissenson et al. | Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney. | |
| JP4625602B2 (ja) | ミオスタチン遺伝子プロモータおよびその活性化阻害 | |
| JP3164865B2 (ja) | 無細胞レセプター結合アッセイ、その作製および使用 | |
| US20050260579A1 (en) | TGF-beta type receptor cDNAs encoded products | |
| CA2082929A1 (fr) | Methodes de detection des agonistes et des antagonistes de l'amyline faisant appel a des recepteurs specifiques | |
| BG102967A (bg) | Модулатори на тъканна регенерация | |
| JP2003530325A (ja) | 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤 | |
| US20080009068A1 (en) | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction | |
| JPH06504842A (ja) | 血小板凝集疾患の特徴付け | |
| EP0313156B1 (fr) | SnRNP-A-antigène et fragments de celui-ci | |
| JP2004500125A5 (fr) | ||
| WO1993004086A1 (fr) | Recepteurs de produits finaux de glycosylation avancee et leurs utilisations | |
| JP2009508532A5 (fr) | ||
| EP4621052A1 (fr) | Sonde de ciblage des cellules immunitaires, reconnaissance de pré-ciblage et système d'administration de médicaments fondé sur les sondes, et son utilisation | |
| EP0771877A1 (fr) | Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse | |
| JP2002509693A (ja) | カドヘリン由来成長因子及びその使用 | |
| US20030073117A1 (en) | Novel protein and gene encoding the protein | |
| WO2000038704A1 (fr) | Utilisation d'un peptide | |
| JP3922345B2 (ja) | 生理活性ペプチド | |
| US20090018071A1 (en) | Epididymis-specific receptor protein | |
| JP4168623B2 (ja) | オリゴペプチド | |
| EP0572122A2 (fr) | Polypeptides comportant une extrémité C modifiée pour la croissance oesteogène | |
| JP2002507385A (ja) | ヒトの５−ｈｔ４セロトニン作動性受容体のスプライシングバリアント、及び、特にスクリーニングのためのその利用 |